Cancer Drug Resistance

cdr

Search

Hot Keywords

Drug Resistance Mechanisms Epigenetic Resistance in Cancer Therapy Biomarkers Pharmacogenetics of Cancer Liquid Biopsy Targeted Cancer Therapy Non-coding RNAs Kinase Inhibitors ABC Transporters

Top

Editorial Board

Editor-in-Chief

Godefridus J. Peters, PhD

gj.peters@amsterdamumc.nl

Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers (Amsterdam UMC), Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Department of Biochemistry, Medical University of Gdansk, Gdansk, Poland.

Research Interests: cancer biomarkers, apoptosis, lung diseases, cell culture, gene expression, pharmacokinetics, pharmacodynamics and pharmacogenetics of anticancer drugs, gastrointestinal cancers, translational research, animal models, drug metabolism and transport, influx and efflux proteins.
Contributions:
SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance

Protective autophagy by thymidine causes resistance to rapamycin in colorectal cancer cells in vitro

Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer

How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?

Cancer drug resistance: a new perspective
Special Issue:
The Role of the Microbiome in Drug Resistance

Advanced Research of Drug Resistance in Gastrointestinal (GI) Cancers

Papers from 43rd Meeting of the European Organization of Research and Treatment of Cancer (EORTC) - Pharmacology and Molecular Mechanisms (PAMM) Group

Editorial Board Members

Aamir Ahmad

Dermatology Institute and Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.

Research Interests: non-coding RNAs expression, signaling in cancer metastasis, circulating and tissue biomarkers.
Contributions:
Epigenetic basis of cancer drug resistance
Special Issue:
Epigenetic Basis of Cancer Drug Resistance
Suresh V. Ambudkar

Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Research Interests: ATP-binding cassette (ABC) drug transporters, drug resistance, membrane biochemistry, chemoresistance, transport proteins.
Yehuda G. Assaraf

Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel.

Research Interests: molecular mechanisms of anticancer drug resistance, drug discovery, physiology.
Benjamin Bonavida

Department of Microbiology, Immunology and Molecular Genetics, Johnsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA, USA.

Research Interests: apoptosis, immunotherapy resistance, cancer drug resistance.
Contributions:
Cell-mediated immune resistance in cancer
Stergios Boussios

Faculty of Life Sciences and Medicine, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.

Research Interests: cancer treatment, cancer in pregnancy, cancer diagnostics, cancer biology, cancer biomarkers, gynaecological cancers, urological cancers, colorectal cancer, autoimmunity.
Ingolf Cascorbi

Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.

Research Interests: cancer biology, pharmacokinetics, genotyping, mutation, DNA, genetics, enzymes, drug safety, pharmaceutical development, intensive care medicine.
Contributions:
Germline variants in cancer therapy
Claudio Cerchione

Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Research Interests: myelodysplastic syndromes, hematological malignancies, lymphoma, multiple myeloma, hematologic diseases, clinical hematology, blood disorders, acute myeloid leukemia, chemotherapy, leukemia, acute lymphoblastic leukemia.
Special Issue:
Research Progress on Drug Resistance in Acute Myeloid Leukemia

Papers from The SOHO (Society of Hematologic Oncology) 4th Italian Conference
Zhe Sheng Chen

Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Queens, NY, USA.

Research Interests: ABC transporters, multidrug resistance, cancer pharmacology.
William C.S. Cho

Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China.

Research Interests: cancer biomarkers, drug repurposing, non-coding RNA, proteomics.
Contributions:
Exosome secretion from hypoxic cancer cells reshapes the tumor microenvironment and mediates drug resistance
Special Issue:
Extracellular Vesicles: Emerging Modulators of Cancer Drug Resistance
Jacqueline Cloos

Department of Hematology, Amsterdam Univerisity Medical Centers location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Research Interests: proteasome inhibitors, minimal residual disease, clonal evolution, splicing, cellular drug addiction, hematology, drug combination studies.
Contributions:
Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradication
Paul Dent

Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA.

Research Interests: cancer therapeutics, rational combination of drugs, molecular mechanisms, drug combinations synergize, breast, brain, liver and pancreatic cancers.
Contributions:
Kinase inhibitors: look beyond the label on the bottle
Changming Dong

School of Chemistry & Chemical Engineering, Shanghai Jiao Tong University, Shanghai, China.

Research Interests: biodegradable polymer nanomedicine; cancer combination therapy; drug delivery systems; multidrug resistance
Thomas Efferth

Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany.

Research Interests: natural product chemistry, medicinal and pharmaceutical chemistry, virtual drug screening, transcriptomics, network pharmacology, biochemistry, drug development, apoptosis, cancer biology.
Contributions:
Drug targets and resistance mechanisms in multiple myeloma
Special Issue:
Drug Resistance in Metastatic Castration-Resistant Prostate Cancer
Wafik S. El-Deiry

Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, MA, USA.

Research Interests: autophagy, p53 tumor suppression, cell death signaling pathways, DNA damage, TRAIL pathway, hypoxia, drug resistance, novel therapeutics, translational oncology.
Marco Falasca

Curtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Perth, Australia.

Research Interests: pancreatic cancer, exosomes, lipid metabolism, membrane transporters, signal transduction, cancer invasion and metastasis, phosphoinositide signalling, cannabinoids.
Special Issue:
Treatment of Pancreatic Cancer
Carlos G. Ferreira

Departamento de Tecnologias da Informação e Educação em Saúde, da Faculdade de Ciências Médicas (FCM), na Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.

Research Interests: immune microenvironment, non-small-cell lung cancer.
Liwu Fu

State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.

Research Interests: ABC transporter, cancer therapy, chemotherapy resistance, multidrug resistance, immune checkpoint blockade, leukemia.
Contributions:
Fusobacterium nucleatum: a new player in regulation of cancer development and therapeutic response
Special Issue:
Tumor Microenvironment and Drug Resistance
David Gewirtz

Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA.

Research Interests: autophagy; senescence; cancer chemotherapy; chemosensitization; radiosensitization; chemtoxicity
Contributions:
An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer
Jean-Pierre Gillet

Laboratory of Molecular Cancer Biology, Faculty of Medicine, University of Namur, Namur, Belgium.

Research Interests: ATP-binding cassette transporters, cancer multidrug resistance mechanisms, pharmacogenomics, cancer biology, transcriptomics.
Elisa Giovannetti, PhD

Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers (Amsterdam UMC), Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Cancer Pharmacology Lab, Fondazione Pisana per la Scienza, Pisa, Italy.

Research Interests: molecular pharmacology, chemoresistance, pancreatic cancer, thoracic cancers.
Contributions:
SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance

Targeted therapies in cancer: where are we going?

Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer
Special Issue:
Targeted cancer therapy

Novel Targets for Therapy Resistant Pancreatic Carcinoma

Papers from 43rd Meeting of the European Organization of Research and Treatment of Cancer (EORTC) - Pharmacology and Molecular Mechanisms (PAMM) Group
William Gmeiner

Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.

Research Interests: colorectal cancer, fluoropyrimidine, thymidylate synthase, DNA topoisomerase, aberrant signaling pathways in tumor cells.
Contributions:
Entrapment of DNA topoisomerase-DNA complexes by nucleotide/nucleoside analogs

Targeting DNA topoisomerases: past & future

Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations
Special Issue:
Targeting DNA Topoisomerases – Past and Future
Sanjay Gupta

Department of Urologic Oncology, Case Western Reserve University, Cleveland, OH, USA.

Research Interests: cancer chemoprevention, cancer therapeutics, drug resistance, drug repurposing, translational oncology, cancer biology, signal transduction, apoptosis, antioxidant activity, artificial intelligence, cancer biomarkers, diet nutrition and cancer, drug delivery, toxicology, epigenetics, inflammation, cancer stem cells.
Contributions:
Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms

Molecular insight: SERPINB3 and AR sensitivity might reduce the risk of COVID-19 infection and complications in prostate cancer patients receiving androgen-deprivation therapy

Dietary phytochemicals and their role in cancer chemoprevention

Role of prostate cancer stem-like cells in the development of antiandrogen resistance

New insights for drug resistance in metastatic castration-resistant prostate cancer

Emerging targets in cancer drug resistance
Special Issue:
Phytochemicals and Cancer Chemoprevention

Genetics and Epigenetics of Prostate Cancer: from Etiology to Treatment
Georg Hempel

Department of Pharmaceutical and Medical Chemistry, Clinical Pharmacy, University of Muenster, Muenster, Germany.

Research Interests: capillary electrophoresis, chromatography, pharmacokinetics, drug safety, oncology.
Dominique Heymann

Institut de Cancérologie de l'Ouest, Tumour Heterogeneity and Precison Medicine Laboratory, Saint-Herblain, France.

Research Interests: circulating tumour cells, pathogenesis of bone sarcoma, osteoclast differentiation, metastatic process.
Contributions:
Exosomal lncRNAs: the newest promising liquid biopsy

Drug resistance in glioblastoma: are persisters the key to therapy?

Biological evidence of cancer stem-like cells and recurrent disease in osteosarcoma
Peter J. Houghton

Department of Molecular Medicine, Greenhey Children’s Cancer Research Institute, UT Health, San Antonio, TX, USA.

Research Interests: pediatric sarcomas, low-grade brain tumors, pediatric cancers of the kidney, nephroblastoma.
Contributions:
Approaches to identifying drug resistance mechanisms to clinically relevant treatments in childhood rhabdomyosarcoma
Zhiqing Huang

Department of Obstetrics and Gynecology, Division of Reproductive Sciences, Duke University Medical Center, Durham, NC, USA.

Research Interests: ovarian cancer; cancer chemoresistance; tumor microenvironment; epigenetics and epigenomics
Thomas Hutson

Baylor Sammons Cancer Center, Texas Oncology, Dallas, TX, USA.

Research Interests: renal cell carcinoma; bladder cancer; prostate cancer; testicular cancer; immunotherapy
Marja Jäättelä

Cell Death and Metabolism, Center for Autophagy, Recycling and Disease, Danish Cancer Society Research Center, Copenhagen, Denmark.

Research Interests: autophagy, cancer progression, lysosomal, DNA, pH regulation.
Gerrit Jansen

Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Location VUmc, Amsterdam, the Netherlands.

Research Interests: rheumatology, cancer biology and immunology, imaging and biomarkers, inflammatory diseases, antifolates, proteasome inhibitors, (multi) drug resistance.
Contributions:
How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?
Markus Joerger

Division of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.

Research Interests: thoracic malignancies, clinical pharmacology, pharmacogenetics, pharmacokinetics, immunotherapy.
Michael Kahn

Department of Molecular Medicine, Beckman Research Institute at City of Hope, Duarte, CA, USA.

Research Interests: chemical genomics, Wnt signaling.
Contributions:
Enhanced Kat3A/Catenin transcription: a common mechanism of therapeutic resistance
Ganna V. Kalayda

Department of Clinical Pharmacy, University of Bonn, Bonn, Germany.

Research Interests: fluorescence microscopy, cell culture, live cell imaging, fluorescence imaging, flow cytometry, western blot analysis, cancer biology, immunofluorescence staining, intracellular trafficking, synthesis.
Hang Fai Kwok

Faculty of Health Sciences, University of Macau, Macau, China.

Research Interests: novel therapeutic antibodies development, venom-based peptide & natural biomolecule prototype drugs development, cancer biomarkers & immunotherapy markers discovery for prognostic and therapeutic validation.
Jonathan A. Ledermann

Cancer Institute, University College London, London, UK.

Research Interests: gynaecological cancers, ovarian cancer.
Contributions:
Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer
Thomas Litman

Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.

Research Interests: bioinformatics, multi-omics, transcriptomics, proteomics, pharmacogenomics, metabolomics, microbiome analysis, machine learning, translational research, biomarker discovery, oncogenomics, multidrug resistance, P-glycoprotein, ABCG2, ATPase activity, transport kinetics.
Special Issue:
ABC Transporters in Multidrug-Resistant Cancer
Jose J.G. Marin

Department of Physiology and Pharmacology, University of Salamanca, Salamanca, Spain.

Research Interests: hepatology and drug targeting, liver and gastrointestinal diseases.
Contributions:
Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma
Giovanni Martinelli

Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Research Interests: leukemia, myelodysplastic syndromes, multiple myeloma, hematologic diseases, lymphoma, blood disorders, stem cell transplantation, chemotherapy, clinical hematology, hematology.
Special Issue:
Research Progress on Drug Resistance in Acute Myeloid Leukemia

Papers from The SOHO (Society of Hematologic Oncology) 4th Italian Conference
Cornelis J. M. Melief

Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, Leiden, the Netherlands.

Research Interests: HLA (human leukocyte antigen), MHC, histocompatibility, immunotherapy, cancer research, clinical immunology, cancer vaccines.
Martin Michaelis

School of Biosciences, University of Kent, Canterbury, UK.

Research Interests: virology, emerging infectious diseases, apoptosis, virus, PCR, cancer cell line.
Contributions:
Drug-adapted cancer cell lines as preclinical models of acquired resistance

What really matters - response and resistance in cancer therapy
Special Issue:
Papers from the BACR Conference-Response and Resistance in Cancer Therapy

Papers from the 2nd BACR Conference "Response and Resistance in Cancer Therapy"
Enrico Mini

Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.

Research Interests: leukemia, antimetabolites and metal-based drug resistance, gastrointestinal cancers, cancer pharmacogenomics, pharmacogenetics.
Contributions:
“Pharmacogenetics of Cancer” - Cancer Drug Resistance special issue
Special Issue:
Pharmacogenetics of cancer

Advanced Research of Drug Resistance in Gastrointestinal (GI) Cancers
Priyabrata Mukherjee

Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

Research Interests: programming tumor microenvironment by nanoparticles, anti-angiogenic property of inorganic nanoparticles, metabolic enzyme and angiogenesis, identification of new molecular targets using nanotechnology, nanoendocytosis, understanding cellular processes using engineered nanoparticles, metabolic enzymes in cancer.
Patrycja Nowak-Sliwinska

School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland; Translational Research Center in Oncohaematology, University of Geneva, Geneva, Switzerland.

Research Interests: multi drug combinations, drug-drug interactions, acquired drug resistance, cancer organoids, cancer treatment, tumor angiogenesis, targeted therapies.
Gianpaolo Papaccio

Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.

Research Interests: cancer stem cells, peritumoral tissue, mitochondrial transfer, organoids, adipose stem cells and cancer, hyaluronans and cancer.
Paola Perego

Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Research Interests: molecular biology, p53, DNA damage, apoptosis, cytotoxicity, pharmacology, cancer cell line.
Contributions:
Tackling cisplatin resistance in ovarian cancer: what can we do?
Special Issue:
Tackling Cisplatin Resistance in Ovarian Cancer
Roger M. Phillips

Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield, UK.

Research Interests: tumour hypoxia, cancer metabolism, hypoxia activated prodrugs, drug discovery (including phenotypic drug evaluation), drug delivery to the tumour microenvironment.
Raphael E. Pollock

Department of Surgery, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.

Research Interests: sarcoma, neoplasms, neurilemmoma, gastrointestinal stromal tumors, breast neoplasms, leiomyosarcoma, neoplasm metastasis, ewing, liposarcoma, myxoid, liposarcoma.
Paolo Ettore Porporato

Department of Molecular Biotechnology and Health Science, Molecular Biotechnology Center, University of Turin, Turin, Italy.

Research Interests: cancer metabolism, muscle atrophy, mitochondrial ROS, cachexia, iron
Chiara Riganti

Department of Oncology, University of Torino, Torino, Italy.

Research Interests: chemo-immunoresistant tumor models, lung cancer, prostate cancer, breast cancer, malignant pleural mesothelioma, glioblastoma multiforme, multiple myeloma.
Contributions:
Overcoming drug resistance in glioblastoma: new options in sight?
Special Issue:
New challenges in overcoming chemoresistance in Glioblastoma
José Rueff

Center for Toxicogenomics and Human Health (ToxOmics), NOVA Medical School-FCM, Universidade Nova de Lisboa, Lisbon, Portugal.

Research Interests: genetics, bacterial cell culture, immunohistochemistry, biochemistry, genomics, PCR, gene expression, cell culture, DNA, cancer biology.
Contributions:
MicroRNAs and cancer drug resistance: over two thousand characters in search of a role

Regulation of ABCB1 activity by microRNA-200c and microRNA-203a in breast cancer cells: the quest for microRNAs’ involvement in cancer drug resistance
Afshin Samali

Apoptosis Research Centre, School of Biological and Chemical Sciences, University of Galway, Galway, Ireland.

Research Interests: apoptosis, endoplasmic reticulum, UPR signaling in cancer, IRE1, PERK, drug discovery, biomarker discovery.
Gautam Sethi

Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Kent Ridge, Singapore.

Research Interests: cancer, cellular and molecular mechanisms, diagnostics and therapeutics, gastrointestinal cancer.
John Seymour

Peter MacCallum Cancer Centre, Royal Melbourne Hospital & University of Melbourne, Victoria, Australia.

Research Interests: haematology, aggressive lymphoma, acute leukemia, myelodysplasia.
Contributions:
Promises and pitfalls of targeted agents in chronic lymphocytic leukemia
Xiang-Yang Shi

State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, Shanghai Engineering Research Center of Nano-Biomaterials and Regenerative Medicine, College of Chemistry, Donghua University, Shanghai, China.

Research Interests: development of organic/inorganic hybrid nanoplatforms and microfluidic platforms for sensing, precision cancer imaging and therapy.
Special Issue:
Nanotechnology Applied to Overcome Tumor Drug Resistance
Alexander Sparreboom

Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, USA.

Research Interests: platinum-based drugs, tyrosine-kinase inhibitors, P-glycoprotein, cancer chemotherapy, sensitivity analysis, clinical pharmacokinetics.
Rakesh K. Srivastava

Stanley S. Scott Cancer Center, School of Medicine, Louisiana State University Health-New Orleans, New Orleans, LA, USA.

Research Interests: apoptosis, cell signaling and human diseases, molecular mechanisms, stem cells and human diseases, nutrition, diet and cancer.
Gary S. Stein

Department of Biochemistry, University of Vermont Larner College of Medicine, Burlington, VT, USA.

Research Interests: breast cancer stem cells, genetic and epigenetic of cancer
Ulrike Stein

Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.

Research Interests: key drivers of metastasis, MACC1, S100A4, cancer cell signaling, cancer metastasis, drug discovery
Chunxia Su

Department of Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China.

Research Interests: non-small cell lung cancer, lung cancer, tumor microenvironment, immunotherapy.
Contributions:
Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer

Immunotherapy resistance of lung cancer

Emerging insights to lung cancer drug resistance
Special Issue:
Lung Cancer Drug Resistance

Lung Cancer Drug Resistance: A New Step Forward
Haruhiko Sugimura

Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Research Interests: cancer biology, genetics, genotyping, cell biology, microscopy, hepatocellular carcinoma, pharmacology, immunohistochemistry, DNA, mutation.
Shi-Yong Sun

Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA.

Research Interests: regulation of death receptors, TRAIL receptors, small therapeutic molecules, drug-induced apoptosis, Akt/mTOR signaling, cancer therapy, EGFR inhibitors, acquired resistance, lung cancer.
Special Issue:
Lung Cancer Drug Resistance

Recent Advances of Cell Death and Drug Resistance
Vladimir P. Torchilin

Center of Pharmaceutical Biotechnology and Nanomedicines, Department of Chemical Engineering, Northeastern University Boston, Boston, MA, USA.

Research Interests: drug delivery, drug targeting, nanomedicine, liposomes, micelles, experimental cancer therapy.
Special Issue:
Overcome Cancer Drug Resistance by Nano-carrier Drug Delivery System
Fatih M. Uckun

Department of Developmental Therapeutics, Immunology and Integrative Medicine, Ares Pharmaceuticals, St. Paul, MN, USA.

Research Interests: immunobiology, immunooncology, systemic inflammation, hematologic malignancies, nanotechnology.
Contributions:
Cancer drug resistance in multiple myeloma

Wilms’ tumor gene (WT1) is strongly expressed in high-risk subsets of pediatric acute lymphoblastic leukemia

Identification and targeting of CD22ΔE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas
Special Issue:
Drug Targets and Resistance Mechanisms in Multiple Myeloma

Contemporary Treatment Strategies for Adolescents and Young Adults with Cancer
Takanori Ueda

Department of Hematology, Matsunami General Hospital, Gifu, Japan.

Research Interests: leukemia, diffuse large B‐cell lymphoma.
Brian A. Van Tine

Department of Medicine, Division of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA.

Research Interests: soft tissue and bone sarcomas, human-in-mouse sarcoma models, amino acid deprivation therapies, metabolic deficiencies in sarcoma, phase 1 clinical trials.
Contributions:
Innate and adaptive resistance mechanisms to arginine deprivation therapies in sarcoma and other cancers

PHGDH as a mechanism for resistance in metabolically-driven cancers

Immune checkpoint inhibitor resistance in soft tissue sarcoma
Special Issue:
Advanced Research of Drug Resistance in Soft Tissue and Bone Sarcoma
Robert C.A.M. van Waardenburg

Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, USA.

Research Interests: DNA repair proteins, cellular response to chemotherapy, protein-protein interactions, post-translational modification by ubiquitin and SUMO, sulfotransferases.
Contributions:
Targeting Tyrosyl-DNA phosphodiesterase I to enhance toxicity of phosphodiester linked DNA-adducts

Targeting DNA repair pathways to overcome cancer drug resistance

Sphingolipid metabolism and drug resistance in ovarian cancer

Targeting DNA topoisomerases: past & future
Special Issue:
Targeting DNA Topoisomerases – Past and Future

Advances in DNA Damage & Repair and Cancer Drug Resistance
Erik A. C. Wiemer

Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.

Research Interests: cancer biology, biomarkers, non-coding RNAs, soft tissue sarcomas, lung cancer, ovarian cancer.
Takahiro Yamauchi

Department of Hematology and Oncology, University of Fukui, Fukui, Japan.

Research Interests: hematologic malignancies, nucleoside analogs, tyrosine kinase inhibitors, bcl2 inhibitors, antibodies, DNA repair, pharmacology.
Nadia Zaffaroni

Molecular Pharmacology Unit, Fondazione IRCSS Istituto Nazionale dei Tumori, Milan, Italy.

Research Interests: telomerase, prostatic neoplasms, melanoma, cisplatin, apoptosis, neoplasms.

Former Editorial Board Member

Joseph R. Bertino

Departments of Pharmacology and Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. (Died October 11, 2021 (aged 91))

Research Interests: cancer biology, lymphomas, antimetabolites.
Special Issue:
Research Progress on Drug Resistance in Lymphomas

© 2016-2023 OAE Publishing Inc., except certain content provided by third parties